ISRCTN72173816进行中（未招募）Unknown
Effect of YAG laser vitreolysis on vitreous structure and visual function in patients with vision degrading myodesopsia secondary to myopic vitreopathy or posterior vitreous detachment
The Retina Clinic London0 个研究点目标入组 50 人开始时间: 2023年7月27日最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Able and willing to give informed consent.
- •2. Age =18 years
- •3. Suffering from symptomatic vitreous floaters visible on contact lens biomicroscopy in one or both eyes.
- •4. Floaters arising from either/both:
- •4.1. Myopic vitreopathy
- •4.2. Posterior vitreous detachment
排除标准
- •1. Present with vitreous opacities outside of the described safety area described in section 3.1.1 (i.e., 3 mm vicinity of the retina and 6 mm vicinity of the lens).
- •2. Visually significant cataract that either causes sufficient media opacity to reduce quality of imaging or would require surgery during the study follow up period.
- •3. High risk of peripheral lesions requiring treatment at the discretion of the local PI during the study period (if patients require and receive treatment for these at screening, they may be rescreened after 2 months following procedure, at the discretion of the PI).
- •4. Vitreous floaters or PVD symptoms present for less than three months.
- •5. Unable to attend study appointments.
- •6. Synchysis scintillans.
- •7. Asteroid hyalosis.
- •8. Vitreous haemorrhage.
- •9. Active photopsia.
- •10. Active uveitis.
- •11. Active proliferative diabetic retinopathy, and/or other significant retinal vascular pathology
- •12. Pre-existing visual field loss (including uncontrolled glaucoma).
- •13. Inherited retinal diseases.
- •14. History of, or active ocular trauma/penetrating ocular injury.
- •15. Any significant vitreoretinopathy e.g., current or previous retinal detachment, epiretinal membrane, macular hole.
- •16. History of previous YAG laser vitreolysis treatments, or previous vitreoretinal surgery for any condition (such as retinal detachment, proliferative diabetic retinopathy).
- •17. History of complicated cataract surgery (e.g anterior vitrectomy).
- •18. History of intraocular surgery within 6 months from starting the study.
- •19. Any other significant ocular or non-ocular condition that, at the discretion of the local PI, puts the subject at risk or influences the results of the study.
- •20. Patients who, in the opinion of the investigator, would be unwilling or unable to provide written informed consent, or undergo the testing procedures as described in the protocol.
- •21. Pregnant or breastfeeding women
研究者
相似试验
已完成
不适用
Study evaluating the safety and efficacy of YAG laser for the treatment of vitreous opacityISRCTN12191616Harbin Aier Eye Hospital306
招募中
2 期
Safety and efficacy in the treatment of vitreous floaters with ophthalmic laserOther vitreous opacitiesH43.3RBR-2jq3v9Instituto de Assistência Médica ao Servidor Público Estadual - SP
已完成
不适用
Nd:YAG Laser Vitreolysis for Symptomatic Vitreous FloatersWeiss RingNCT05800353Hainan Province Liu Zhongmin Expert Team Innovation Center70
已完成
不适用
Capsulotomy YAG LaserRefractive and Accommodative DisordersNCT02993081Instituto de Olhos de Goiania67
已完成
不适用
comparative study of the effect by Er:YAG laser on palpebral conjunctivaJPRN-UMIN000026735Haneginomori Eye Clinic60